Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE: atezolizumab + bevacizumab as neoadjuvant plus adjuvant treatment for resectable high-risk hepatocellular carcinoma
2025-521459-22-00Phase 2Authorised
- Sponsor
- IDIBAPS
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by IDIBAPS. Primary endpoint: Recurrence-free survival. Planned start Nov 2025; status: authorised.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2025-521459-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521459-22-00.